scispace - formally typeset
J

Joel Shapiro

Researcher at Erasmus University Rotterdam

Publications -  41
Citations -  3253

Joel Shapiro is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Chemoradiotherapy & Neoadjuvant therapy. The author has an hindex of 22, co-authored 37 publications receiving 2559 citations. Previous affiliations of Joel Shapiro include Rochester General Health System & Utrecht University.

Papers
More filters
Journal ArticleDOI

Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline

TL;DR: It is demonstrated that doxycycline inhibits the growth of DLBCL cells both in vitro and in mouse xenograft models, and the deneddylating activity of COP-9 signalosome (CSN) is revealed as a novel target of doxy cycline and it is suggested that doXYcycline may represent a promising therapeutic agent forDLBCL and other non-Hodgkin lymphomas subtypes.
Journal ArticleDOI

Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer

TL;DR: A nomogram for the prediction of pathologically complete response after neoadjuvant chemoradiotherapy was developed, with a reasonable predictive power, but needs external validation before it can be used for individualised clinical decision-making.
Journal ArticleDOI

Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer

TL;DR: Factors that influence patients' preferences, and trade‐offs that patients are willing to make in their choice between surgery and active surveillance were investigated here.
Journal ArticleDOI

Thoracic Involvement With Pheochromocytoma: A Review

TL;DR: A case of endobronchial metastases in a 37-year-old woman known to have a recurrent extra-adrenal pheochromocytoma is reported, believed to be the first reported case ofEndobron chial phechromocyToma reported in the world.